Brachial plexus schwannoma mimicking advanced breast carcinoma.

CONCLUSION: The best of our knowledge it is the third description of brachial plexus schwannoma associated with breast cancer and the first with a synchronous association. The knowledge of this pathology and its potential to alter treatment justify the reporting of the present case. PMID: 32083563 [PubMed - as supplied by publisher]
Source: Breast Disease - Category: Cancer & Oncology Tags: Breast Dis Source Type: research

Related Links:

ConclusionsIn patients with TNBC-NST, intra-E and intra-N did not correlate with pCR, but intra-E did positively correlate with tumor size. NST may exhibit a greater response to NAC, regardless of whether intra-E or intra-N is present or not on the pretreatment MRI.Key Points• Pathological complete response in TNBC-NST had no correlation with intramammary edema or intratumoral necrosis.• NAC may be justified in TNBC-NST even in the presence of edema or necrosis.• The extension of edema correlated with tumor size of TNBC-NST.
Source: European Radiology - Category: Radiology Source Type: research
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ConclusionsHER2 IHC DIA connectivity is the most important factor predicting pCR to anti-HER2 neoadjuvant chemotherapy in patients with HER2-positive breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Febres-Aldana CA, Kuritzky N, Krishnamurthy K, Poppiti R, Howard L Abstract BACKGROUND: Hormone-receptor-negative breast carcinoma (HRNBC), including triple-negative and HER-2 amplified tumors, can overexpress P16INK4a with substantial contribution to tumor progression. In nonneoplastic cells, P16INK4a mediates growth arrest and senescence secondary to cytotoxic compounds. OBJECTIVE: We assessed the impact of neoadjuvant chemotherapy (NAC) on P16INK4a expression in breast specimens. METHODS: P16INK4a and CD-44 were evaluated by immunohistochemistry in biopsies and subsequent post-NAC excision in a ...
Source: Breast Disease - Category: Cancer & Oncology Tags: Breast Dis Source Type: research
In this study, we examine the indications, complications, and long-term outcomes of therapeutic NSM. METHODS: From 2003 to 2016, women undergoing NSM for invasive cancer or ductal carcinoma in situ (DCIS) were identified from a prospectively maintained database. Patient and disease characteristics were compared by procedure year, while complications were compared by procedure year using generalized mixed-effects models accounting for a random surgeon effect. Overall survival and time to recurrence were examined. RESULTS: Of the 467 therapeutic NSMs, 337 (72%) were invasive cancer, 126 (27%) were DCIS, and 4 (1%) ...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
In this study, we examine the indications, complications, and long-term outcomes of therapeutic NSM.MethodsFrom 2003 to 2016, women undergoing NSM for invasive cancer or ductal carcinoma in situ (DCIS) were identified from a prospectively maintained database. Patient and disease characteristics were compared by procedure year, while complications were compared by procedure year using generalized mixed-effects models accounting for a random surgeon effect. Overall survival and time to recurrence were examined.ResultsOf the 467 therapeutic NSMs, 337 (72%) were invasive cancer, 126 (27%) were DCIS, and 4 (1%) were phyllodes t...
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: The pre-treatment tumor SUVmax could be utilized as an independent imaging biomarker of the tumor aggressiveness and poor prognosis. Risk stratification based on this index could play a pivotal role in alteration of treatment planning, such as neoadjuvant chemotherapy (precision oncology). PMID: 31587025 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
ConclusionsMRI demonstrated good accuracy in predicting pCR after NAC among the breast cancer patients examined. However, non-mass enhancement at pre-treatment MRI negatively affected the diagnostic performance of MRI in assessing treatment response after NAC.
Source: European Journal of Radiology - Category: Radiology Source Type: research
AbstractBackgroundThe density of tumor-infiltrating lymphocytes (TIL) is a predictive factor for response to neoadjuvant systemic therapy (NAST) in breast cancer. High TIL density correlates with higher complete pathologic remission (pCR) in triple negative and HER2 positive breast cancer. Additionally, not only TIL density but also subsets of immune cells in tumor stroma seem to play an important role in cancer and immune cell interaction and response to chemotherapy. Our aim is to determine TIL density and expression of CD 20, CD3, CD8, PD-L1, FOXP3 and PGM1 on core biopsy specimen and find a correlation with pCR.Trial d...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
This 61-year-old woman presented with new primary triple negative breast cancer (TNBC) in the lateral breast 10 years after completing radiation for ductal carcinoma in situ (DCIS) in the same breast.1 Despite neoadjuvant chemotherapy and mastectomy with only residual DCIS and negative nodes, patient developed a TNBC re-recurrence only 9 months later. She was treated with chemotherapy, and there remains positive residual localized disease by positron emission tomography (PET). At this point we recommend the following.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pathology